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ABSTRACT
The recent rapid development of COVID-19 vaccines offers 
hope in addressing the worst pandemic in a hundred 
years. However, many countries in the Global South face 
great difficulties in accessing vaccines, partly because of 
restrictive intellectual property law. These laws exacerbate 
both global and domestic inequalities and prevent 
countries from fully realising the right to health for all their 
people. Commodification of essential medicines, such as 
vaccines, pushes poorer countries into extreme debt and 
reproduces national inequalities that discriminate against 
marginalised groups. This article explains how a decolonial 
framing of human rights and public health could contribute 
to addressing this systemic injustice. We envisage a 
human rights and global health law framework based 
on solidarity and international cooperation that focuses 
funding on long- term goals and frees access to medicines 
from the restrictions of intellectual property law. This would 
increase domestic vaccine production, acquisition and 
distribution capabilities in the Global South.
INTRODUCTION
The COVID-19 pandemic is one of the biggest 
health crises that the world has faced in the 
last century. While many COVID-19 vaccines 
have been rapidly developed, offering hope 
to billions, many countries face a herculean 
task in accessing them, in part because of 
restrictive intellectual property (IP) laws. This 
is because vaccine patents, which are a form of 
IP rights, lead to production monopolies that 
contribute to increased prices and decreased 
access. This injustice has been described as 
‘vaccine apartheid’ because it creates stark 
disparities in vaccine access between coun-
tries in the Global North and those in the 
Global South, as well as between elites and 
others within countries.
In this article, we show that the existing 
application of IP law exacerbates already 
severe global and domestic inequalities and 
prevents many countries in the Global South 
from progressively realising the right to 
health for all of their people. This, in turn, 
amounts to a violation of states’ human rights 
obligations to respect, protect and fulfil the 
right to health. We suggest that the best way 
to address these structural global inequities is 
through a decolonised approach to human 
rights in global health. Decolonisation refers 
to the undoing of colonial rule over subor-
dinate countries but has taken on a wider 
meaning as the ‘freeing of minds from colo-
nial ideology’, in particular by addressing 
the ingrained idea that to be colonised was 
to be inferior. Decolonisation enables us to 
critique positions of power and dominant 
culture.1 In global health, decolonisation is 
a political tradition rooted in Global South 
struggles against colonisation, exploitative 
‘development’ agendas, apartheid and access 
to public health, including inequity in access 
to essential medicines.2 Calls to decolonise 
global health are not new, and indeed they 
have gained urgency due to the power asym-
metries illustrated by the COVID-19 crisis.3 4 
In this paper, a ‘decolonial’ framing of human 
rights in global health enables us to focus on 
ways in which structural or systemic issues 
reproduce inequalities and, we hope, can 
Summary box
 ► Restrictive intellectual property laws inhibit access 
to essential medicines such as vaccines.
 ► Commodification of essential medicines such vac-
cines can push countries into greater indebtedness 
and increase national and international inequalities.
 ► A decolonised approach to human rights in glob-
al health can enable us to address this systemic 
injustice.
 ► A decolonised approach demands three things. 
Firstly, reparative justice, not through charitable 
models such as COVAX but through redistribution, 
secondly increasing manufacturing capacity of 
states from the global south and thirdly that states 
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help to galvanise more effective human rights struggles 
from below.5–8 In order to do so, we call for reparative 
redistributing of resources in global solidarity, shifting 
vaccine access from a charitable plea to a legal obligation, 
increasing manufacturing capacity in the Global South 
and clarifying human rights responsibilities of pharma-
ceutical corporations themselves.
International and domestic responses to COVID-19, 
including in respect of vaccine access, have been highly 
politicised.9 Thus, a decolonised approach allows us to 
consider ways in which the entire patent regime—and 
existing interpretations of international human rights 
law that defer to its applications—commodifies essen-
tial medicines, undermining universal health coverage. 
In this article, we illustrate how, beyond making essen-
tial medicines unaffordable for countries in the Global 
South, the commodification of vaccines is pushing coun-
tries into greater indebtedness and reproducing national 
inequalities through dual- track systems that discriminate 
against poorer and marginalised groups, thereby making 
it harder for these countries to achieve the realisation of 
the right to health for all.
The commodification of essential medicines is the 
consequence of the prevalent system of global capitalism 
that allows manufacturers and states to value financial 
profit over human life. In this paper, we define neoco-
lonialism to mean that although many global South 
States are outwardly independent and sovereign in many 
respects, they remain beholden both to states in the 
Global North and increasingly to multinational corpora-
tions.9 This relationship is exemplified in the case of IP 
rights protections, which low and middle- income coun-
tries (LMIC) are pressured into adopting and respecting 
in order to enter into bilateral or regional free trade or 
investment agreements with high- income countries and/
or receive investments and loans from global financial 
institutions.10
In this paper, we first outline what a human rights 
approach to realising access to COVID-19 vaccines entails 
when a decolonising lens is not used. We illustrate the 
limitations of this approach in our discussion of the 
competing IP framework which governs IP rights and 
stymies the human rights frameworks for access to essen-
tial medicines such as vaccines. We reveal the resulting 
inequalities both between countries and within coun-
tries. Finally, we outline how a decolonised approach 
could improve access to vaccines both, for this crisis and 
also for future crises.
A HUMAN RIGHTS APPROACH TO REALISING ACCESS TO 
COVID-19 VACCINES
International human rights law provides a universal 
framework for advancing global health with justice, 
transforming moral imperatives into legal entitlements. 
The right to the highest attainable standard of health, 
first articulated in 1946 in the WHO Constitution, has 
evolved through the progression of treaties such as the 
International Covenant on Economic, Social and Cultural 
Rights (ICESCR).11 Nearly every country in the world has 
now ratified at least one international agreement that 
imposes specific obligations that lead to the realisation 
of the right to health, including explicit obligations to 
prevent, treat and control epidemics.12
In the specific context of COVID-19 vaccines, the 
United Nations (UN) Committee on Economic, Social 
and Cultural Rights (CESCR), responsible for inter-
preting the ICESCR, has emphasised that states ‘have 
a duty to prevent intellectual property and patent legal 
regimes from undermining the enjoyment of economic, 
social and cultural rights’, and that the IP regime should 
be interpreted and implemented in a manner supportive 
of the duty of states ‘to protect public health’.13 This duty 
has been extended to equitable global vaccine distribu-
tion to prevent the spread of infectious diseases such 
as COVID-19.14 Vaccine access should not be a ques-
tion of charity but of states fulfilling their human rights 
commitments under international law. The high cost of 
COVID-19 vaccines hinders the realisation of a range of 
human rights, including the rights to life, equal benefit 
from scientific progress and health. The CESCR, which 
recognises vaccines as vital to the realisation of the right 
to health, has argued that inflexibly applied IP systems 
and rules that commodify vaccines perpetuate health 
inequalities and violate human rights.15
Ensuring equitable access will require waiving patent 
law where it undermines state obligations to realise the 
right to health.
Legal frameworks establish IP and prioritise patents over 
health
Global health law encompasses the legal norms, 
processes and institutions needed to create the condi-
tions for people throughout the world to attain the 
highest possible level of physical and mental health.16 
The legal landscape for global health is fragmented, with 
multiple competing actors and regimes covering areas 
such as health security, border control, surveillance, 
trade and IP.17 At the intersection of global health and 
human rights, this fragmentation is further exacerbated 
by a division of global health law into separate regimes 
emanating from the International Health Regulations 
(IHR), on the one hand, and international human rights 
law, on the other. This has led to calls for global health 
law and human rights law to be ‘harmonized’.18
The development and dissemination of COVID-19 
vaccines has highlighted how the international legal 
system pertaining to global health is driving global health 
inequalities instead of alleviating them. As a result, in 
part, of neocolonial ‘development’ models that promote 
inequitable IP laws, most of the vaccine supply has been 
manufactured in the Global North and purchased by 
governments in those countries to be stockpiled for their 
own populations—a practice sometimes described as 
‘vaccine hoarding’ or ‘vaccine nationalism’.19 20
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Even where countries in the Global South have 
produced vaccines themselves in significant quantities, 
they have sometimes been guilty of perpetuating ineq-
uity of other Global South countries through vaccine 
nationalism and vaccine diplomacy, in which vaccines are 
offered to poorer countries in order to achieve geopo-
litical objectives.21 22 A decolonised approach to global 
health enables us to conceptualise this behaviour as a 
reproduction of a neocolonial system which pits some 
formerly colonised countries against others.23 24 This 
has meant that some countries in the Global South also 
benefit from this uneven system, and they too contribute 
to the exploitation of poorer countries in the Global 
South.21
Although the WHO cocreated the COVAX Facility, a 
donor- funded mechanism that seeks to pool procure-
ment to enhance access to vaccines for LMICs, the char-
itable funding scheme is facing a serious shortfall in 
meeting global needs. The WHO has estimated that most 
people in LMICs will not be vaccinated until the end of 
2023,25 and even this estimate may be optimistic, given 
the delays in initial distributions through COVAX.26
This prompts the obvious question: How is it that 
existing legal mechanisms, or at least the prevailing inter-
pretations and understandings of them, have permitted 
and even enabled this inequity? International IP law 
embedded in international trade agreements allows 
pharmaceutical companies time- limited rights to prevent 
others from making, using or selling their patented inven-
tion without permission. Under the 1995 Agreement on 
Trade- Related Aspects of Intellectual Property Rights 
(TRIPS), which was included in the Uruguay Round of 
multilateral trade negotiation, pharmaceutical companies 
have at least 20 years from filing a patent to profit from 
their investments in developing, testing and upscaling 
pharmaceutical products throughout the world.27 This 
protection is given to pharmaceutical companies to 
incentivise them to engage in greater research and 
development for new drugs. However, there is evidence 
that challenges previous assumptions about the linkages 
between Research and Development spending and inno-
vation for essential medicines.28 The current COVID-19 
crisis has brought this into sharp focus, with projections 
that the global public sector had spent at least €93 billion 
on the development of COVID-19 vaccines and therapeu-
tics—€85.6 billion of this on vaccines.29
Global IP rights, whether adopted in accordance with 
TRIPS, or subsequent bilateral and multilateral agree-
ments, are part of a wider legal system which facilitates 
global neocolonialism. For instance, powerful actors 
such as the European Union (EU) and the USA have 
included TRIPS- plus provisions in bilateral and multilat-
eral agreements. These agreements often force countries 
of the Global South to concede to more stringent patent 
protections in order to gain trade advantages and also to 
escape trade sanctions.30
In so doing, IP law commodifies medicines that are 
essential to human survival and well- being, and sacrifices 
the lives and health of the poor and otherwise margin-
alised on the altar of corporate profitability.31 Common 
interpretations and understandings of the international 
IP system are that healthcare goods and services derive 
their value from their tradability.14 (‘We use the term 
“public good” as it is used in global health to mean a 
good that should be available universally because of its 
critical importance to health, and not as the term is used 
in economics to mean a good that is both non- excludable 
and non- rivalrous.’)14 32 However, many, including critical 
Global South scholars, have questioned the prioritisation 
of property rights (including IP rights) over other rights 
(especially the rights to health, life and equal benefit 
from scientific progress) in a manner that is inconsistent 
with international human rights law.31
Many low- income countries have long been active in 
resisting the IP system as an unjust extension of a colonial 
trade system. At the height of the HIV pandemic, in which 
millions of people in the Global South were denied life- 
saving medicines, civil society treatment access campaigns 
galvanised states within the World Trade Organization 
(WTO) into agreeing to the Doha Declaration on TRIPS 
and Public Health.33 This WTO Declaration recognises 
human rights and allows states to use all of the ‘flexibil-
ities’ within the TRIPS regime to protect public health, 
acknowledging the need for access to medicines in a 
public health emergency.34 However, this international 
consensus on IP has always been strongly contested by 
pharmaceutical companies and their host governments, 
predominantly in the Global North.
This remarkably strong resistance to employing TRIPS 
flexibilities has continued in the current COVID-19 crisis, 
as the attempts of countries largely from the Global South 
to try to obtain a TRIPS waiver to increase their supply of 
vaccines for COVID-19 have been unsuccessful. Although 
the USA has recently supported a watered- down version 
of a TRIPS waiver, it remains far from certain whether 
other states in the Global North will support this prior-
itisation of health over IP rights, or whether this would 
be sufficient, as we discuss in the section on flexibilities 
below.
Rather than allowing for equitable vaccine access as 
a human right for all people everywhere, states have 
instead turned to a charitable donation and market 
purchase scheme through the COVAX initiative. This 
type of model, which focuses on charity and not rights, 
is consistent with exactly the kind of understandings 
of human rights and public health that are in need of 
decolonisation. While there have been public consensus 
statements issued by the Human Rights Council, in which 
states have agreed that all states have the right to access 
vaccines and the right to use TRIPS flexibilities, this state-
ment reflects a disappointing failure to acknowledge any 
corresponding state obligations to employ such flexibili-
ties.35 This has allowed countries from the Global North, 
and their few Global South allies, to agree to this state-
ment and support the right to vaccine access rhetorically, 
and in principle within the Human Rights Council, while 
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resisting any calls for a TRIPS waiver within the WTO, 
and thus consolidating a denial of their obligations to 
employ TRIPS flexibilities.
The failure of TRIPS flexibilities
Although countries from the Global South have the 
option of engaging TRIPS flexibilities in the absence of a 
general waiver, they often do not do so because the process 
of using these flexibilities is often stacked against them, 
reproducing neocolonial dynamics. For instance, TRIPS 
allows states with limited manufacturing capacity to waive 
a patent for a limited duration so as to import essential 
medicines through a compulsory licence. However, in 
practice, this process is lengthy and complex, as it relies 
on ensuring that both the importing and exporting 
countries have enacted local laws that permit them to 
use TRIPS flexibilities. Further, the importing country 
needs to negotiate with the pharmaceutical company in 
order to establish a fair price, which is always tricky, but 
made significantly more difficult in a crisis. To date, this 
process has been used only once, when Rwanda obtained 
access to generic antiretrovirals through an importa-
tion agreement with the Canadian company Apotex. 
However, even in that context, although Rwanda notified 
the WTO Council of its intention to use the mechanism 
in July 2007, it took 15 months before it could import its 
first batch of antiretrovirals. Despite its strong support, 
the manufacturer Apotex felt that the process was too 
cumbersome to use again.36
This complexity has been heightened during the 
COVID-19 crisis due to the speed at which vaccines were 
manufactured, which has created a lack of transparency 
around the patent process.37 Thus, the Bolivian govern-
ment, which is seeking to use TRIPS flexibilities through 
compulsory licences, recognises in their application 
that there is a lack of clarity around the exact extent 
of product and process patents for any of the existing 
COVID-19 vaccines due to inadequate information about 
manufacturing or regulatory processes in different coun-
tries.38 Additionally, many countries that have manufac-
turing capacity, such as those in the EU, have not sought 
to support countries in the Global South that want to use 
these flexibilities. In sum, cumbersome rules, political and 
economic pressures and a lack of transparency conspire 
to enable the Intellectual Property Regime (IPR) system 
to sustain and deepen global health inequities.
Entrenching inequalities between countries
The current global distribution of COVID-19 vaccines 
is largely dictated by power disparities and inequities in 
financial and other resources, with predominantly high- 
income countries contracting bilaterally with individual 
pharmaceutical companies (many in their own coun-
tries) for specific vaccines, leaving countries from the 
Global South facing inequitable vaccine access. Bilateral 
deals between states and pharmaceutical companies, 
whether completed by Global North or Global South 
states, significantly compromise the effectiveness and 
equity of the COVAX initiative, limited as it already is by 
the coercive influence, vested interests and participation 
of pharmaceutical companies and their host nations. The 
African Union, for example, endorsed the TRIPS waiver 
to relax WTO rules so that LMICs could create their 
own COVID-19 vaccines, but this collective effort across 
African countries faced resistance from Global North 
countries and pharmaceutical companies.
The IP system appears to have pushed countries in the 
Global South that may prefer not to be dependent on 
the charitable model of the COVAX scheme to join high- 
income countries in engaging directly with manufac-
turers to purchase COVID-19 vaccines. This has included 
African countries, despite the African Union’s criticism 
of the inequities resulting from IP law protections. This 
process has reproduced colonially entrenched power 
dynamics, in which poorer countries lack the bargaining 
power to obtain competitive rates and, consequently, 
typically end up paying far more than the wealthier, 
developed countries. More broadly, countries in the 
Global South are pressured into participating in global 
systems of trade that result in the exploitation of their 
own populations by unjust global economic systems and 
IP laws.39 The high cost of vaccines for countries from 
the Global South constitutes a large proportion of their 
health expenditure, and this comes at the expense of 
other health priorities.
In many cases, the only way in which Global South 
countries can purchase vaccines is to move themselves 
further into debt. Given the detrimental neocolonial 
implications of debt, with a long history of loan condi-
tionalities through structural adjustment programmes, 
increasing debt to service health needs contributes to the 
worsening of inequalities between the Global North and 
Global South.40 These programmes may increase debt 
and undermine development in ways that limit the real-
isation of the right to health.41 The World Bank has set 
aside US$12 billion and has already disbursed loans of 
US$500 million for vaccines in low- income and middle- 
income nations;42 poorer nations, instead of servicing 
already depleted health systems, are forced to divert addi-
tional funds to servicing debt.
Entrenching inequalities within countries
The high costs of vaccines also propagate inequalities 
within nations, as desperate countries try to recoup some 
of the costs by charging their people for vaccine access 
or using complex arrangements that prioritise some 
people over others. Egypt, for instance, is charging for 
the COVID-19 vaccine, which is likely to exclude the 
poorest people, who have already been severely affected 
by the crisis.43 In reality, it also means that wealthier indi-
viduals are prioritised, as they usually find it easier to pay 
for access. Those able to access vaccines in these coun-
tries, very often a small economic and political elite, are 
often in positions of power precisely along the lines of 
existing global inequalities and often to the prejudice 
of groups marginalised on the basis of gender, race and 
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other grounds of discrimination prohibited under inter-
national human rights law.
Facilitating vaccine access for more affluent members 
of society reinforces power structures at the expense of 
marginalised populations. In South Africa, conservative 
non- governmental organisations aligned closely with 
the interests of the white minority and elite corporate 
interests launched a court challenge in order to procure 
private supplies of vaccines, bypassing the nationwide 
mechanisms set up by the government to ensure equi-
table vaccine access. However, having faced opposition 
from human rights activists and the South African govern-
ment, this litigation was ultimately withdrawn. (For more 
information on this litigation see ref 44 45.) Kenya has also 
prioritised diplomats for COVID-19 vaccination at the 
expense of health workers, and Indonesia has suggested 
that the ‘more productive’ members of society be vacci-
nated first.46 47 In other countries, such as Peru, political 
elites and their families and friends were secretly vacci-
nated before the broader populations. (See as examples 
ref 48 49.)
An important issue at the boundary of national and 
international concerns is the potential use of ‘vaccine 
passports’.50 Free movement of goods is integral to one 
of the core objectives of the IHR, and yet many govern-
ments are proposing the use of COVID-19 vaccination 
passports as a mechanism for reopening their econo-
mies, which would discriminate against those who have 
not been vaccinated. The EU introduced vaccine pass-
ports in the summer of 2021 for entry into the eurozone 
and excluded vaccines that were made from the Serum 
Institute in India which is responsible for the majority 
of vaccines provided in the Global South.51 Vaccination 
disparities both within and between countries mean that 
many people in LMICs are unlikely to be vaccinated until 
2023; therefore, vaccine passports would only further 
exacerbate both national and global inequalities and 
disproportionately restrict the rights of large swathes 
of the global population from exercising their right to 
freedom of movement on an equal basis.
TOWARDS A DECOLONISED APPROACH TO HUMAN RIGHTS FOR 
VACCINE ALLOCATION
A decolonised approach to human rights demands that 
providing access to essential therapeutics such as vaccines 
should be prioritised through domestic, regional and 
international funding mechanisms to ensure that all 
states have adequate resources for the realisation of 
the right to health—including in the present context 
of COVID-19 vaccines—within a public health crisis 
brought about by a pandemic. This therefore neces-
sitates a radical rethinking of the ways in which frag-
mented legal regimes—through international trade law 
for IP and international human rights law for the right to 
health—serve to reinforce patent law at the expense of 
access to vaccines. The process of decolonisation involves 
centring human rights differently. Human rights are no 
longer understood as being detached from geopolitics or 
history but transformed to serve those whose rights are 
being violated.52 We suggest three ways in which decol-
onisation can ‘radically reconceptualise’ global health.53
Entrenching solidarity: reparations as a response to global 
inequalities
Under the ICESCR and IHR, states have a duty to coop-
erate with other states in progressively realising the right 
to health, including ensuring provision of minimum 
levels of health services, facilities and goods on a non- 
discriminatory basis.54 55 The CESCR has clarified that, 
in the context of COVID-19, this duty should include: 
‘sharing of research, medical equipment and supplies, 
and best practices in combating the virus; coordinated 
action to reduce the economic and social impacts of the 
crisis; and joint endeavours by all States to ensure an 
effective, equitable economic recovery’.56 Additionally, it 
affirmed that ‘the needs of vulnerable and disadvantaged 
groups as well as fragile countries, including least devel-
oped countries, countries in conflict and post- conflict 
situations, should be at the centre of such international 
endeavours’.56
Many statements from various UN treaty bodies have 
acknowledged that ensuring universal access to essen-
tial medicines is central to the realisation of the right to 
health, and that IP considerations should never over- ride 
human rights obligations for universal and equitable 
access to the COVID-19 vaccine.57–62 These statements 
have been achieved through a global movement of soli-
darity, encompassing states, civil society organisations and 
individuals, and reflect a reassessment of human rights 
values from below. For instance, the Special Rapporteur 
on the right to health has argued that solidarity needs to 
be part of a wider effort to redistribute health resources. 
However, these statements need to go further and call 
for explicit reparations in global health, which is the only 
way to redistribute health resources globally.4 63
Increased financing could fund public research and 
development through either WHO’s existing efforts for 
a complementary research and development treaty,64 or 
through mechanisms such as the proposed Pandemic 
Financing Facility. The latter proposes to mobilise long- 
term contributions of approximately US$5–US$10 billion 
per annum to finance preparedness, but should also focus 
on funding research and development on pathogens so 
as to restructure patents as a global public good.65 For 
those states unable to fund their own access to COVID-19 
vaccines, there is an international human rights duty on 
other states to ensure that such states are not harmed 
through the actions of multilateral institutions that leave 
them with devastating debt (The Maastricht Principles 
(see note 57), Principles 3, 4 and 9).66
In meeting these international obligations immediately 
to ensure access to COVID-19 vaccines, only a few coun-
tries are capable of manufacturing the vaccine at the scale 
needed.67 This inequity in vaccine production capacity 
requires countries from the Global North to support 
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countries in the Global South to increase their produc-
tion capacity, including through non- exclusive licensing 
and the WHO’s COVID-19 Technology Access Pool.68 
Sharing technology and building manufacturing capacity 
will be critical to ensuring that countries can solve prob-
lems of access to essential medicines in the long term, 
setting a precedent that will be necessary in addressing 
environmental justice, antimicrobial resistance preven-
tion and other global public goods.
Increased funding, as a form of reparations, would 
help finance a more equitable manufacturing base to 
ensure that all countries in the Global South are not 
totally reliant on existing manufacturers. Although we 
acknowledge that the manufacturing of vaccines is a 
complex process and that not every country is likely 
to manufacture medicines including vaccines at the 
required scale, the WHO has projected that at present, 
five African countries have some capacity to manufacture 
vaccines, and efforts to finance manufacturing capacity 
for countries of the Global South would go a long way 
towards readdressing the charity model proposed under 
COVAX by ensuring that African countries can rely on 
regional compacts for their vaccine access. Coordination 
and cooperation within the African Union and the Africa 
Centres for Disease Control and Prevention, which has 
already begun, could determine the strategically best, 
and most effective, locations and ways to scale up manu-
facturing on the continent to improve vaccine access.69 70
Human rights obligations beyond the state
A decolonial approach to human rights acknowledges 
the historical and present- day role of corporations in the 
perpetuation of poverty and inequality and must deal 
head on with the ethical and legal obligations of corpo-
rations in global health. Human rights communities have 
struggled to attribute human rights responsibilities to 
corporations due to the historical fixation on the state 
as the locus of human rights obligations. While interna-
tional human rights law now recognises a direct respon-
sibility on corporations to respect human rights, including 
the right to health,71 72 this has been understood largely 
only as a negative obligation, urging them not to make 
human rights outcomes worse (see note 54).71 A decolo-
nial approach must challenge the systems that sustain 
IP inequalities in preventing access to vaccines. To do so 
necessitates being clearer about the human rights norms 
and principles that apply to non- state actors, such as 
corporations.73
States have obligations to regulate corporations such as 
pharmaceutical companies effectively in order to ensure 
that they are not violating the right to health (see note 
56).54 Such regulatory measures must be implemented 
within domestic, regional and international platforms, 
including through multilateral institutions, such as 
the WHO and the WTO. In taking this responsibility 
seriously, states would need to work towards greater 
coherence, which would avoid weaker human rights obli-
gations within trade- related forums such as the WTO. 
Other global health bodies, such as the IHR, as well as 
any proposed new pandemic treaty, will need to ensure 
that they are not merely diluting these corporate respon-
sibilities but trying to clarify and strengthen them in line 
with international human rights law.
Our push for a radical and decolonised understanding 
of human rights demands that we move away from ‘an 
emergent trade- related, market- friendly paradigm of 
human rights’ to human rights that are grounded in the 
experiences of people from the Global South.74 Thus, 
a decolonised approach to human rights requires us to 
expand our understanding of obligations of corporations 
to avoid measures and practices which: exacerbate supply 
scarcity or delays in access to COVID-19 vaccines; exac-
erbate lack of affordability of COVID-19 vaccines; omit 
principles of equity and non- discrimination from their 
business decisions; and lack transparency or prevent states 
from providing information about their interactions 
in relation to essential medicines such as vaccines.74 75 
By denying people vaccines, states are subject to worse 
health outcomes, thus falling short of their negative 
duties, but we also need to compel corporations to be 
more proactive in respecting human rights and consider 
strongly what positive duties they may carry in terms 
of international human rights law. While this may be 
anathema to international human rights law at present, it 
is not without its supporters and effective domestic prece-
dent. (General Comment 24 (see note 74) which refers to 
a judgement of the South African Constitutional Court in 
Daniels v Scribante and others, case CCT 50/16, judgement 
of 11 May 2017, paras 37–39 in which positive duties were 
imposed on a private owner of land. See also ref 76.)
Refocusing on human rights as political tools of activism
Human rights are inherent, and therefore they act as 
the locus for all forms of emancipation or possibilities 
that enable people to avoid suffering. Rights are there-
fore tactics that are employed by people, states and 
other actors to seek protections for themselves and other 
actors. Additionally, decolonising human rights also has 
policy implications, and broader implications for an 
overall approach to public health and human rights. This 
is why the UN Special Rapporteur on Health has recently 
framed her entire mandate through a lens of decoloni-
ality as a mechanism of challenging epistemic failures 
that challenge the realisation of the right to health.77
In our analysis, we have pointed out that although 
there are broader struggles between the Global North 
and Global South countries, the neocolonial landscape 
within which IP rights exist also benefits some countries 
of the Global South, such as India and China, who are 
now engaged in vaccine diplomacy. At the national level, 
we also see inequalities that serve the elite over marginal-
ised groups, such as refugees or migrants. A decolonised 
approach to human rights must be rooted in the experi-
ences of those whose rights are violated.
Countries in the Global South should ensure that they 
treat the COVID-19 vaccine as an essential medicine, 
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which is part of states’ core obligations under the right 
to health, and must therefore be realised immediately, 
universally and without discrimination. We argue that 
COVID-19 vaccines should be available free at the point 
of access and that all inhabitants of every country are 
given access to such vaccines without discrimination, 
and prioritised in accordance with health vulnera-
bility rather than financial resources. Allowing for, and 
contributing to, the perpetuation of dual tracks that 
entrench inequalities violates these binding human 
rights obligations.
CONCLUSION
As scholars and activists from the Global North and 
Global South who have been advocating for the full 
realisation of human rights throughout the pandemic, 
especially around access to essential medicines such as 
COVID-19 vaccines, we intend this article to contribute 
to a broader conversation on the need for the decoloni-
sation of human rights in global health and to illustrate 
that human rights should be more emancipatory. Human 
rights require equality in access to vaccines, rather than 
the limited and ineffective charity currently made avail-
able in a glacial manner through initiatives like COVAX.
For Global South countries, the decolonisation of 
human rights in health is a potentially radical and trans-
formative agenda, which would contribute to ensuring 
that vaccines are provided equitably, transparently, freely 
and universally at the point of access. It would contribute 
towards breaking the spell of regressive and inflexible 
application of patents acting as the over- riding consid-
eration in all matters of vaccine production and distri-
bution. The COVID-19 vaccination process is one of the 
greatest global health challenges of our time, and we 
must ensure that we use this moment to better concep-
tualise the ways in which we collectively think about the 
right to health of all people, everywhere.
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